// Real-Time Intelligence Feed

Financial Intelligence.
Real-Time.

SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.

22,616
Stories Indexed
Live
Feed Status
6
Data Sources
LATEST
AllEarningsFDAM&AInsider TradingRegulatoryOfferingLeadershipRestructuringDividendInstitutional HoldingsBankruptcy
FDA · 22,616 results Live
FDA ALMAJECT Jun 4 — 0.00

FDA Approves Unknown Drug — ALMAJECT

FDA approved ALMAJECT’s therapeutic product NDA218771, signaling a new addition to the market with potential to address significant unmet medical needs. This regulatory milestone p…

FDA IPCA May 29 — 0.00

FDA Approves Unknown Drug — IPCA LABS LTD

# FDA Approves IPCA Laboratories' Generic Drug Application IPCA Laboratories Limited received FDA approval for an abbreviated new drug application (ANDA 209855) on May 29, 2024, e…

FDA Elite May 16 — 0.00

FDA Approves METHOTREXATE SODIUM — Elite Laboratories, Inc.

# FDA Approves Elite Laboratories' Generic Methotrexate Sodium Oral Formulation Elite Laboratories, Inc. has received FDA approval for its generic methotrexate sodium oral formula…

FDA Dr. May 8 — 0.00

FDA Approves VASOPRESSIN — Dr. Reddy's Laboratories, Inc.

Dr. Reddy's Laboratories received FDA approval for its intravenous vasopressin generic, positioning the company to immediately capture market share in the competitive hospital ther…

FDA Neurocrine Apr 30 — 0.00

FDA Approves INGREZZA SPRINKLE — Neurocrine Biosciences, Inc.

# FDA Approves Neurocrine Biosciences' INGREZZA SPRINKLE for Tardive Dyskinesia Treatment Neurocrine Biosciences, Inc. has received FDA approval for INGREZZA SPRINKLE (valbenazine…

FDA AbbVie Apr 26 — 0.00

FDA Approves RINVOQ — AbbVie Inc.

Attribution of this breakthrough can be reserved for the **AbbVie** approval of the oral rheumatoid arthritis therapy RINVOQ (upadacitinib). The nod reflects intense **market** com…

FDA Scienture Apr 19 — 0.00

FDA Approves REZENOPY — Scienture LLC

Scienture LLC announced FDA approval for REZENOPY, a generic naloxone hydrochloride nasal spray, marking the company’s entry into the rapid-growth market for essential opioid rever…

FDA La Apr 3 — 0.00

FDA Approves ZEVTERA — La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company secured FDA approval for ZEVTERA (ceftobiprole medocaril sodium), positioning itself in the IV antibiotic market to address resistant bacterial infe…

FDA Akebia Mar 27 — 0.00

FDA Approves VAFSEO — Akebia Therapeutics, Inc.

# FDA Approves Akebia Therapeutics' VAFSEO for Anemia Treatment The FDA has approved Akebia Therapeutics' VAFSEO (vadadustat), an oral hypoxia-inducible factor (HIF) stabilizer, p…

FDA Merck Mar 26 — 0.00

FDA Approves WINREVAIR — Merck Sharp & Dohme LLC

# FDA Approves Merck's WINREVAIR (sotatercept-csrk), Expanding Treatment Options in Pulmonary Hypertension Market Merck Sharp & Dohme LLC's FDA approval of WINREVAIR (sotatercept-…

FDA Idorsia Mar 19 — 0.00

FDA Approves TRYVIO — Idorsia Pharmaceuticals Ltd

Idorsia Pharmaceuticals Ltd announced on March 19, 2024, that the FDA granted approval for TRYVIO (aprocitentan) to treat pulmonary arterial hypertension, marking a significant val…

FDA Madrigal Mar 14 — 0.00

FDA Approves REZDIFFRA — Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals’ FDA approval of RESMETIROM (Resmetirom) for the treatment of non-alcoholic steatohepatitis确立了首个获批用于该适应症的口服疗法,预计将确立公司作为慢性肝病治疗领域关键参与者的领先地位。 这一里程碑式的监管覆盖有望诱发强…

FDA Advagen Mar 5 — 0.00

FDA Approves OXCARBAZEPINE — Advagen Pharma Ltd.

Advagen Pharma Ltd. announced the March 5 FDA approval of its ANDA207717 for the oral formulation of oxycarbazepine, providing clearance to market the anticonvulsant generic. The c…

FDA BluePoint Mar 5 — 0.00

FDA Approves CAPECITABINE — BluePoint Laboratories

BluePoint Laboratories has received marketing authorization from the FDA for its generic version of CAPECITABINE, positioning the firm to capturemarket share amid expected competit…

FDA Fresenius Mar 5 — 0.00

FDA Approves TYENNE — Fresenius Kabi USA, LLC

Fresenius Kabi USA has announced FDA approval of tocilizumab (Tyenne, BLA761275) for the treatment of moderate to severe active rheumatoid arthritis, signaling the company’s contin…

FDA Padagis Feb 22 — 0.00

FDA Approves LENALIDOMIDE — Padagis US LLC

Padagis US LLC announced the FDA approval of its oral lenalidomide ANDA, positioning the company to compete in the generic oncology market where an influx of supply is expected to …

FDA Kanchan Feb 14 — 0.00

FDA Approves OXCARBAZEPINE — Kanchan Healthcare Inc

Kanchan Healthcare Inc. has achieved FDA approval for its ANDA-217782, launching the generic version of oxcarbazepine oral tablets. The move positions the manufacturer to capture m…

FDA Macleods Feb 8 — 0.00

FDA Approves FENOFIBRIC ACID — Macleods Pharmaceuticals Limited

Macleods Pharmaceuticals Limited has received FDA Approval for its Abbreviated New Drug Application (ANDA207796) for generics of the Hypercholesteremia treatment FENOFIBRIC ACID, s…

FDA Aurobindo Jan 29 — 0.00

FDA Approves ISOTRETINOIN — Aurobindo Pharma Limited

# FDA Approves Generic Isotretinoin ANDA from Aurobindo Pharma Aurobindo Pharma Limited received FDA approval for its generic isotretinoin oral formulation (ANDA218194) on January…

FDA Aurobindo Jan 24 — 0.00

FDA Approves LACOSAMIDE — Aurobindo Pharma Limited

# FDA Approves Generic Lacosamide from Aurobindo Pharma The U.S. Food and Drug Administration has approved Aurobindo Pharma Limited's generic lacosamide oral formulation, expandin…